Clinical Trial Update: PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for ADI-PEG 20 in adults with non-Hodgkin's lymphoma who failed prior therapy completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED